Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moss GenomicsFRA:F73 EBIT per Share is €-0.02 as of Mar. 2026. Among 524 Healthcare Providers & Services companies, Moss Genomics ranks better than 60.11% on this metric.
Moss Genomics's EBIT per Share for the
three
months ended in Mar. 2026 was €0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 18.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Moss Genomics's EBIT per Share or its related term are showing as below:
FRA:F73'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 18.9 Med: 18.9 Max: 18.9
Current: 18.9
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Moss Genomics was 18.90% per year. The lowest was 18.90% per year. And the median was 18.90% per year.
FRA:F73's 3-Year EBIT Growth Rate is ranked better than 60.11% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs FRA:F73: 18.90
Moss Genomics's EBIT for the
three
months ended in Mar. 2026 was €0.02 Mil.
Moss Genomics (FRA:F73) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Moss Genomics EBIT per Share Related Terms
Moss Genomics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Moss Genomics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moss Genomics (FRA:F73) has a EBIT per Share of €-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Moss Genomics and its competitors. According to the industry distribution chart, Moss Genomics ranks #209 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 39.9%.
Is Moss Genomics' EBIT per Share too high?
Moss Genomics' current EBIT per Share is €-0.02. Based on the distribution chart, Moss Genomics ranks #209 out of 524 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Moss Genomics' EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Moss Genomics ranks #209 out of 524 companies for EBIT per Share. This puts Moss Genomics in the upper half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Moss Genomics and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moss Genomics's current EBIT per Share is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moss Genomics stock overvalued right now?
Moss Genomics (FRA:F73) has a current EBIT per Share of €-0.02. The current EBIT per Share is €-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Moss Genomics (FRA:F73), the current EBIT per Share is €-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moss Genomics Inc is an emerging consumer genomics company that provides personalized health, anti-aging, and wellness solutions based on genomic, microbiome, and epigenome data. It aims to eliminate barriers in healthcare by offering accessible, affordable at-home testing along with easy-to-understand actionable results.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F73 has been successfully added to your 
